Insider Purchase: CEO & President of $AIM (AIM) Buys 60,110 Shares

Quiver QuantitativeNov 20 13:00 ET

Express News | AIM ImmunoTech Form4 Filing Shows CEO And President Thomas K Equels Bought 60,110 Shares At An Average Price Of $0.18/Share

BenzingaNov 20 12:55 ET

AIM ImmunoTech Announces Data Pubished on Part 1 Study on Ampligen

TipRanksNov 19 08:11 ET

AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer

BenzingaNov 19 08:02 ET

AIM ImmunoTech Announces Publication of Breast Cancer Data From Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

GlobeNewswireNov 19 08:00 ET

Express News | Roswell Park's Phase 1 Trial Results For Triple-Negative Breast Cancer, With 66% Achieving Complete Or Near-Complete Remission And No Immune-Related Adverse Events; Findings Published In Journal For ImmunoTherapy Of Cancer

BenzingaNov 18 13:16 ET